Targeted therapy for high-risk BRAF-mutated thyroid cancer
Treatments studied
Part of Cancer, Hormones & metabolism clinical trials.
This trial tests two targeted drugs, vemurafenib and cobimetinib, for people with high-risk thyroid cancer that has a specific BRAF V600E mutation. The goal is to see if this combination can help prevent the cancer from coming back after surgery or other initial treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a certain type of thyroid cancer that has a BRAF V600E gene mutation.
- Your cancer must be considered "high risk" for recurrence, meaning it has spread outside the thyroid, involves large lymph nodes, or has other concerning features.
- You cannot have had previous treatment with drugs that target BRAF or MEK (like vemurafenib or cobimetinib) or certain other targeted therapies.
- You must be at least 18 years old, have good organ function (kidneys, liver, blood counts), and controlled blood pressure.
- You must be willing to avoid pregnancy or father a child by using effective birth control during and for a year after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies whether targeted medicines (dabrafenib and trametinib) plus radiation can control an aggressive thyroid cancer with a specific BRAF gene change. It may help by attacking cancer cells that have this mutation and using focused radiation to improve tumor control.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
This trial tests whether giving targeted drugs before surgery can shrink advanced thyroid cancers that are hard to remove. It uses genetic test results to match you to a specific treatment arm, aiming to make surgery safer and more successful.
This trial tests whether giving a targeted therapy pill (which attacks cancer cells with a BRAF mutation) before and after surgery can help treat anaplastic thyroid cancer that hasn't spread to other organs. It's for people whose cancer has a specific gene change (BRAF V600E or V600K) and who are healthy enough for surgery.
This study tests a new combination of targeted drugs (dabrafenib and trametinib) compared to chemotherapy (cabozantinib) for people with a specific type of advanced thyroid cancer called BRAF-mutated differentiated thyroid cancer. The goal is to see which treatment works better.
This trial tests whether combining two targeted cancer medicines—vemurafenib and cobimetinib—can treat adults whose tumors have a specific “BRAF V600” mutation. You may be screened with blood tests and a tissue biopsy before starting treatment.
Hear when a new Thyroid Gland Follicular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.